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Definition of diabetes
Patients were defined as diabetic at baseline (type 1, type 2 or uncertain type) based on coded diagnoses recorded in CPRD or HES on or before study entry ( Figure S1 ). Lists of Read and ICD-10 diagnostic codes which convey diabetic status are curated on the CALIBER data portal (https://www.caliberresearch.org/portal/chapter/6). The aim of this algorithm is to identify patients with type 2 diabetes. The majority of diabetic patients in this cohort have type 2 diabetes, and we are not aiming to identify all patients with type 1 diabetes (this algorithm would not be suitable for a study focusing on type 1 diabetes). Our algorithm does not use any information after study entry to classify patients, in order to reduce immortal time bias. However this bias is not eliminated completely because specific type 1 or type 2 codes may have been entered retrospectively only for patients who survived. Our algorithm leaves many patients with an unclassified type of diabetes. However, rather than using a more complex algorithm, we carried out sensitivity analyses with different definitions (e.g. the type 2 definition or any diabetes).
Definition of endpoints
Cardiovascular phenotype definitions based on the CALIBER data sources are curated on the CALIBER data portal (www.caliberresearch.org/portal).
Stable angina was defined by a coded diagnosis in primary or secondary care of ischaemic chest pain or stable angina, a positive myocardial ischaemia test, two or more prescriptions of antianginal medication, or coronary revascularisation.
Unstable angina was defined as a primary or secondary care diagnosis of unstable angina, or an acute coronary syndrome without myocardial infarction recorded in the disease registry. Coronary disease not further specified is a non-specific diagnosis of ischaemic or coronary heart disease in primary or secondary care that does not fall into one of the more specific categories. It was not included among the 12 diseases in the main displays of hazard ratios, but for cumulative incidence calculations it was combined with unstable angina.
Non-fatal myocardial infarction was defined as a disease registry diagnosis of an acute coronary syndrome with elevated troponin, or a primary or secondary care diagnosis of myocardial infarction.
Unheralded coronary death was death with the primary cause certified as coronary heart disease, and no prior history of cardiovascular disease. Patients with myocardial infarction who died on the day of their infarct were considered to have unheralded coronary death.
Heart failure was defined by coded diagnoses in primary care, secondary care and death certificates.
Arrhythmia or sudden cardiac death was a composite of ventricular arrhythmias, cardioversion procedures, implantable cardioverter defibrillator, and sudden cardiac death. It was defined using diagnoses and procedure codes in primary care, secondary care and death certificates.
Transient ischaemic attack was defined by coded diagnoses in primary or secondary care.
Ischaemic stroke was defined using coded diagnoses in primary care, secondary care and death certificates. Patients with a procedure code for carotid endarterectomy within 90 days of a stroke of unspecified type were considered to have ischaemic stroke. 'Stroke not further specified' is a diagnosis of stroke which does not state it is ischaemic or haemorrhagic. This clinical event was not included among the 12 diseases in the main displays of hazard ratios, but for cumulative incidence calculations it was combined with ischaemic stroke.
Subarachnoid haemorrhage was defined by coded diagnoses in primary care, secondary care and death certificates.
Intracerebral haemorrhage was defined by coded diagnoses in primary care, secondary care and death certificates.
Peripheral arterial disease includes intermittent claudication, limb ischaemia or gangrene due to atherosclerotic disease in the arteries of the legs. It was defined by coded diagnoses and procedures in primary care, secondary care and death certificates.
Abdominal aortic aneurysm was defined by coded diagnoses and procedures in primary care, secondary care and death certificates.
Sample size
We used all eligible patients in the CALIBER database for this study. We carried out a power calculation for estimating the age-adjusted hazard ratio between type 2 diabetes and haemorrhagic stroke, one of the less common endpoints, using the powerSurvEpi package in R. 6 Based on our dataset, with 1·8% of patients having type 2 diabetes and correlation coefficient between type 2 diabetes and age ρ² = 0·018, a sample size of 1 000 000 would give 76% power to detect a hazard ratio of 1·5 with a type I error rate of 5%, and a sample size of 1 500 000 would give 90% power.
Multiple imputation
Multiple imputation was implemented using the mice 7 algorithm in the statistical package R, to replace missing values in exposure and risk factor variables. Imputation models were estimated separately for men and women and included:
1. All the baseline covariates used in the main analysis (age, quadratic age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions); 2. Prior (between 14 and 4 years before study entry) and post (between 0 and 1 year after study entry) averages of continuous covariates in the main analysis; 3. Baseline measurements of covariates not considered in the main analysis (diastolic blood pressure, alcohol intake, white cell count, haemoglobin, creatinine, alanine aminotransferase); 4. Baseline medications (low-dose aspirin, loop diuretics, oral contraceptives and hormone replacement therapy); 5. Coexisting medical conditions (history of depression, cancer, renal disease, liver disease and chronic obstructive pulmonary disease);
6. The Nelson-Aalen hazard and the event status for each endpoint analysed in the data. 8 Non-normally distributed variables were log-transformed for imputation and exponentiated back to their original scale for analysis. Five multiply imputed datasets were generated, and Cox models were fitted to each dataset. Coefficients were combined using Rubin's rules. The Kolmogorov-Smirnov test was used to compare the distribution of observed versus imputed log-transformed covariates.
Survival analysis and competing risks
We carried out survival analysis to describe and model the first occurrence of any cardiovascular disease. A patient's follow-up ended when they experienced one of the cardiovascular endpoints or when they were censored. Subsequent events (e.g. MI occurring after stable angina) were not analysed.
To describe the incidence of each initial presentation over time we constructed cumulative incidence curves, taking into account the other possible initial presentations as competing events. Normal-based confidence intervals were constructed based on Greenwood's variance formula, as implemented in the R prodlim package.
For multivariable modellling we considered using Cox models (for modelling cause-specific hazards) or the Fine and Gray model (to compare cumulative incidence curves by modelling subdistribution hazards). As the aim of this study was observational epidemiology -to explore associations rather than predict risk -we considered cause specific hazard ratios to be appropriate quantities to estimate. They should be interpreted together with cumulative incidence curves but cannot be used to predict cumulative incidence. We also found the Fine and Gray model to be more computationally intensive, and it would require significant software engineering and/or computing time to apply it to the large dataset used in these analyses. We used follow-up time as the timescale for the Cox models. Tables  Table S1. Inclusion criteria Unstable angina or coronary disease not further specified
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Death from other causes without any cardiovascular disease prior to death 
Arrhythmia or sudden cardiac death
Stroke not further specified
Abdominal aortic aneurysm 0·46 (0·35-0·59) < 0·0001 0·49 (0·38-0·63) < 0·0001 0·52 (0·40-0·67) < 0·0001
Other death 1·10 (1·05-1·17) 0.0004 1·01 (0·96-1·07) 0·70 1·04 (0·992-1·09) 0·11
All analyses used the complete dataset with multiple imputation of missing covariate values. 'Risk factors' comprised body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure and smoking status. Heart failure 3·01 (2·22-4·07)
Other death
These analyses were limited to the subset of individuals with completely recorded covariate information: 59 116 with no diabetes and 12 411 with type 2 diabetes. 'Risk factors' comprised body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure and smoking status. Ischaemic stroke 1·72 (1·54-1·92) < 0·0001 1·42 (1·00-2·01) 0·051
Abdominal aortic aneurysm 0·49 (0·39-0·62) < 0·0001 0·33 (0·15-0·72) 0·0056
Hazard ratios were adjusted for age, sex, risk factors (body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status), and statin and antihypertensive prescription in the year before study entry. Our algorithm leaves many patients with an unclassified type of diabetes. However, rather than using a more complex algorithm, we carried out sensitivity analyses with different definitions (e.g. the type 2 definition or any diabetes).
Lists of Read and ICD-10 diagnostic codes which convey diabetic status are curated on the CALIBER data portal (https://www.caliberresearch.org/ portal/chapter/6). Figure S2 . Association of type 2 diabetes with initial presentation of cardiovascular diseases using different adjustments 'Risk factors' adjustment includes age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, and smoking status. 'Treatment' includes statins and antihypertensive prescription in the year before study entry. P values *** < 0·001, ** < 0·01, * < 0·05 Figure S3 . Adjusted hazard ratios for type 2 diabetes and initial presentations of cardiovascular diseases by age group
A. CALIBER phenotype algorithm for diabetes B. Patient flow diagram
Hazard ratios by age group for the association of different initial presentations of cardiovascular disease with type 2 diabetes, adjusted for sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 0·05 Figure S4 . Association of type 2 diabetes with initial presentation of cardiovascular diseases by level of glycaemic control.
Hazard ratios for initial presentations of cardiovascular diseases associated with type 2 diabetes with different levels of HbA1c (mean in mmol/mol within 3 years of baseline), compared with no diabetes, adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 0·05 Figure S5 . Association of type 2 diabetes with initial presentation of cardiovascular diseases using different subsets of the data sources.
Hazard ratios adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 0·05 Figure S6 . Schoenfeld residuals and tests for proportional hazards Scaled Shoenfeld residuals for type 2 diabetes versus no diabetes, adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. The lines show the estimate and 95% confidence interval for the beta coefficient for type 2 diabetes over time. The top left corner of each graph contains ρ, χ² and p value for the correlation between transformed survival time and scaled Schoenfeld residuals. For clarity, points plotted on the graph are for a random sample of 20 000 patients rather than all 1.9 million.
